title: The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.
abstract: In recent years, the emergence of the oligometastatic state has called into question whether patients found to have a limited or low metastatic tumor burden may benefit from locally ablative therapy (LAT). In the past two decades, stereotactic body radiation therapy has been increasingly used to safely deliver LAT and provide high local control in nonoperable non-small-cell lung cancer patients. Mostly retrospective analyses suggest that using LAT for oligometastatic disease in non-small-cell lung cancer offers excellent local control and may provide an improvement in progression-free survival. Any meaningful improvement in cancer-specific survival remains debatable. We examine the role of integrating LAT in this patient population and the rationale behind its use in combination with targeted therapy and immunotherapy.
authors.affiliation: Department of Internal Medicine, Division of Hematology/Oncology, University of New Mexico School of Medicine, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131, USA.|Hematology/Oncology Fellowship Program, University of New Mexico School of Medicine, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131, USA.
authors.forename: Pranshu
authors.initials: P
authors.lastname: Bansal
authors.affiliation: Department of Radiation Oncology, University of Colorado School of Medicine, University of Colorado, Aurora, CO, USA.
authors.forename: Chad
authors.initials: C
authors.lastname: Rusthoven
authors.affiliation: Department of Internal Medicine, Division of Hematology/Oncology, University of New Mexico School of Medicine, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131, USA.|Cancer Genetics, Epigenetics & Genomics Research Program, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131, USA.
authors.forename: Yanis
authors.initials: Y
authors.lastname: Boumber
authors.affiliation: Department of Internal Medicine, Division of Hematology/Oncology, University of New Mexico School of Medicine, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131, USA.|Section of Radiation Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131, USA.|Cancer Therapeutics: Technology, Discovery & Targeted Delivery Program, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131, USA.
authors.forename: Gregory N
authors.initials: GN
authors.lastname: Gan
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000556:secondary / Q000628:therapy; D001932:Brain Neoplasms / Q000556:secondary / Q000628:therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D003110:Colonic Neoplasms / Q000473:pathology / Q000628:therapy; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D018773:Genes, erbB-1; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D009154:Mutation; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D018579:Patient Selection; D011379:Prognosis; D016634:Radiosurgery / Q000009:adverse effects / Q000191:economics / Q000379:methods*; D014178:Translocation, Genetic; D016896:Treatment Outcome
chemical_list: C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion
keywords: ALK; EGFR; NSCLC; PD-1; SBRT; immunotherapy; localized therapy; metastatectomy; oligometastases; oligoprogression